Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
There is a continuing need for alternative treatment options for a substantial proportion of patients with respiratory disorders such as asthma and chronic obstructive pulmonary disease. Writing in Science Translational Medicine, teams led by Brightling, Milligan and Tobin report that agonists of free fatty acid receptor 4 (FFA4) can dampen asthma-like symptoms in mice, indicating its potential as a novel therapeutic target.